How to Appeal an Anthem (Elevance Health) Prior-Authorization Denial for Weight-Loss Medication

By the PriorAuthAppeal editorial team · Sources cited · Independent of Anthem (Elevance Health)

Last reviewed 2026-05-06

Getting denied for Wegovy, Saxenda, or Zepbound by Anthem (Elevance Health) is frustrating — but it is rarely the end of the road. Anthem covers all three medications under its Clinical UM Guideline: Anti-Obesity Agents when patients meet a specific set of criteria: a BMI of 30 or higher, or 27 or higher with at least one recognized weight-related comorbidity, plus documented lifestyle effort and a completed or documented-failed trial of phentermine or two other oral anti-obesity agents. This guide walks you through exactly what Anthem requires, why denials happen, and how to build an appeal letter that speaks directly to the insurer's own policy language.

At a glance

• Covered drugs: Wegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3 mg), Zepbound (tirzepatide)
• BMI threshold: BMI ≥ 30, OR BMI ≥ 27 with at least one recognized weight-related comorbidity
• Recognized comorbidities: Type 2 Diabetes, Hypertension, Dyslipidemia, Obstructive sleep apnea, Coronary artery disease
• Step-therapy requirement: Trial and failure (or documented contraindication/intolerance) of phentermine for at least 12 weeks, OR trial and failure of two oral anti-obesity agents — applies to all three covered drugs unless contraindication is documented in the chart
• Lifestyle documentation required: Adherence to a reduced-calorie diet and increased physical activity for at least 6 continuous months, documented in the medical record
• Appeal deadline: 180 days from the date of denial notice
• Internal appeal levels: 2
• External review: Available after exhausting internal appeals

How Anthem decides whether to cover GLP-1 medications

Anthem's coverage determination for Wegovy, Saxenda, and Zepbound follows its Clinical UM Guideline: Anti-Obesity Agents, and every criterion in that guideline must be satisfied — not most of them, all of them. Think of the policy as a checklist with four mandatory gates.

The first gate is your BMI. Anthem requires a BMI of at least 30, measured and documented in the medical record. If your BMI is between 27 and 29.9, you still qualify — but only if your chart also documents at least one of these comorbidities: Type 2 Diabetes, Hypertension, Dyslipidemia, Obstructive sleep apnea, or Coronary artery disease. A comorbidity that isn't on that list — even one that is medically serious — will not satisfy this criterion under the current guideline.

The second gate is lifestyle documentation. Anthem requires documented adherence to a reduced-calorie diet and increased physical activity for at least 6 months before it will approve a GLP-1 agent. "Documented" is the operative word. Good intentions and verbal reports don't count. The notes in your medical record must reflect that your physician discussed, tracked, and documented your participation in a diet and exercise program over a continuous six-month period.

The third gate is step therapy. Anthem requires a trial and failure — meaning you tried it, used it for at least 12 weeks, and did not achieve adequate response — of phentermine, or alternatively a trial and failure of two separate oral anti-obesity agents. The only way to bypass this requirement is if your physician documents a clinical contraindication or intolerance to phentermine (and any alternative agents, as applicable) directly in your chart. This is not optional language Anthem sometimes applies; their guideline notes that step therapy applies unless contraindication is documented.

The fourth gate is safety screening. Anthem will not cover these medications for patients with a personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, or severe pancreatitis. These are absolute exclusions rooted in the FDA labeling of GLP-1 receptor agonists, and no appeal will overcome them if they apply.

Clinical support for this class of medications is substantial. The AACE/ACE Comprehensive Clinical Practice Guidelines (Garvey et al. 2023, published in Endocrine Practice) classify obesity as a chronic disease requiring evidence-based pharmacotherapy when lifestyle intervention alone is insufficient. The American Diabetes Association Standards of Care 2025, Section 8, explicitly recommends GLP-1 receptor agonists for patients with Type 2 Diabetes and excess weight. The Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity supports pharmacotherapy as an adjunct to lifestyle modification — exactly the scenario Anthem's own policy envisions.

What makes Anthem's policy distinct from other insurers

Anthem's 12-week minimum duration requirement for phentermine step therapy is more specific than many competitors' policies, which often require only a documented "trial" without naming a minimum duration. That specificity cuts both ways: if you have a chart note showing less than 12 weeks of phentermine use, Anthem may argue the trial was inadequate even if you experienced a side effect that prompted discontinuation. Your physician's note must explicitly characterize the outcome — intolerance, contraindication, or failure — and connect it to clinical reasoning.

Anthem's recognized comorbidity list is narrower than some peer insurers. Five conditions are listed: Type 2 Diabetes, Hypertension, Dyslipidemia, Obstructive sleep apnea, and Coronary artery disease. Several conditions that other major insurers recognize — such as non-alcoholic steatohepatitis (MASH/NASH), polycystic ovarian syndrome (PCOS), or osteoarthritis — do not appear in Anthem's current Clinical UM Guideline. If your most prominent comorbidity is one that doesn't appear on that list, your appeal strategy must shift: your physician will need to document a listed comorbidity that may be present but underemphasized in the chart, or address the BMI threshold directly.

The two-tier internal appeal structure combined with the 180-day deadline creates a meaningful strategic window that many patients don't use. Some insurers allow only 60 or 90 days for first-level appeals. Anthem's 180-day window gives you time to gather missing documentation, obtain a specialist letter, or correct coding errors before you file — but that window starts on the date of the denial notice, not the date you open the letter.

The most common reasons Anthem denies these requests

Anthem's most frequent denial code for GLP-1 medications is CO-50 (not medically necessary), which is a catch-all that typically signals the submitted documentation did not satisfy one or more of the four coverage criteria. The second most common is N-431 (step therapy required), meaning Anthem's records show no completed trial of phentermine or two oral anti-obesity agents. The third is N-130 (plan limitation), which can indicate that your specific benefit plan excludes weight-loss drugs entirely — a structurally different problem from a medical necessity denial.

The practical causes behind these codes are usually predictable. Missing or vague lifestyle documentation is the most common root issue — chart notes that mention "counseled on diet and exercise" in passing across six months are not the same as documented adherence to a structured program. Step-therapy gaps come next: either the phentermine trial wasn't documented, lasted fewer than 12 weeks, or the outcome wasn't characterized as a failure or intolerance. BMI not recorded at the time of the prior authorization request is another frequent miss. And sometimes the denial is simply a coding error — the wrong diagnosis code was submitted, or the drug was billed under a benefit tier that excludes it.

How to address each denial reason

A CO-50 (not medically necessary) denial requires you to directly cross-reference Anthem's own Clinical UM Guideline: Anti-Obesity Agents and demonstrate, criterion by criterion, that the patient record satisfies each requirement. Your appeal letter should quote the guideline's specific language, then cite the corresponding chart note, date, and page.

An N-431 (step therapy required) denial is addressable in two ways. If you completed a phentermine trial of at least 12 weeks and it failed, your physician must submit a letter — or an amended chart note — that explicitly states the drug, the dates of use, the duration, and the clinical outcome. If phentermine is contraindicated (for example, due to a history of cardiac arrhythmia, hyperthyroidism, or a documented drug interaction), your physician must document that contraindication with ICD-10 coding and clinical explanation. Vague notes will not suffice.

An N-130 (plan limitation) denial requires a different approach. First, obtain your Summary Plan Description (SPD) and verify whether your plan explicitly excludes weight-loss medications. If it does, a medical necessity appeal has limited leverage — the fight shifts to arguing that the exclusion violates federal law (see the statutes section below), or to escalating to your employer's HR department if this is an employer-sponsored plan. If the SPD does not contain a clear exclusion, argue that the denial is a wrongful application of a limitation that does not exist in your plan documents.

Federal and state laws that protect your right to appeal

ACA Section 2719 (implemented via 29 CFR 2560.503-1 for ERISA plans) requires insurers to provide a full and fair review of every adverse benefit determination. Practically, this means Anthem must tell you in writing exactly which criteria you failed to meet, give you access to the clinical guidelines it relied on, and allow you to submit additional evidence at each internal appeal level.

ERISA Section 503 (29 CFR 2560.503-1) applies to most employer-sponsored plans (not marketplace or Medicaid plans). It sets specific procedural floors: Anthem must issue a decision on a first-level internal appeal within 30 days for pre-service claims (claims decided before you receive care), and 60 days for post-service claims. If Anthem misses these deadlines, you may be entitled to escalate directly to external review.

ACA Section 1557 prohibits discrimination in health coverage on the basis of disability. Obesity is recognized as a chronic disease — a classification supported explicitly by the AACE/ACE 2023 guidelines — and an appeal can argue that blanket exclusion of pharmacological treatment for obesity, while covering pharmacotherapy for other chronic conditions, constitutes disability-based discrimination under Section 1557.

After exhausting both internal appeal levels, you have the right to request independent external review through a federally certified Independent Review Organization (IRO). The IRO's decision is binding on Anthem. Requesting external review preserves your legal options and is free to you as a plan member.

What a strong appeal letter contains

A strong Anthem GLP-1 appeal letter leads with the denial code and your member ID, then states immediately which specific criterion Anthem claimed was unmet. Every subsequent paragraph addresses one criterion from the Clinical UM Guideline: Anti-Obesity Agents and pairs it with a piece of documentation.

Your letter should include:

• A direct quote of the relevant criterion from Anthem's Clinical UM Guideline, followed by chart evidence that the criterion is satisfied
• Your physician's most recent documented BMI measurement with the date of measurement
• A summary of the six-month lifestyle intervention, citing specific chart note dates
• Documentation of the phentermine trial (drug name, start date, end date, outcome) or a physician attestation of contraindication with supporting ICD-10 code
• A statement confirming the absence of medullary thyroid carcinoma, MEN-2, or severe pancreatitis history
• A reference to the AACE/ACE 2023 clinical practice guidelines and the ADA Standards of Care 2025, framing the requested medication as standard of care
• If applicable, a citation of ERISA Section 503 / 29 CFR 2560.503-1 noting the insurer's obligation to provide a full and fair review

Avoid writing in an emotional tone — appeals are reviewed by clinicians and medical directors, not customer service agents. Write clinically, write specifically, and match Anthem's language as closely as possible.

Timeline: what happens after you submit your appeal

The clock starts the moment Anthem receives your appeal — not the day you mail it, so use certified mail or the member portal to create a timestamped record.

• Days 1–30: Anthem must issue a first-level internal appeal decision within 30 days for pre-service (prior authorization) appeals under 29 CFR 2560.503-1
• Days 30–60: If denied at the first level, you may file a second-level internal appeal; Anthem again has 30 days to respond to a pre-service claim
• After second-level denial: You may request independent external review immediately; the IRO typically issues a decision within 45 days for standard reviews, or 72 hours for expedited reviews involving urgent medical need
• 180-day hard deadline: All internal appeals must be filed within 180 days of the original denial notice — missing this window forfeits your internal appeal rights

Track every communication in writing. Save confirmation numbers, portal screenshots, and certified mail receipts. If Anthem fails to respond within its required timeframe, document that failure and raise it in your escalation.

Frequently asked questions about Anthem GLP-1 appeals

Does Anthem require a phentermine trial even if my doctor thinks it's the wrong drug for me?

Anthem requires a trial and failure OR a documented contraindication or intolerance — your doctor's clinical judgment counts, but only if it is written into your medical record with specific clinical reasoning. A note that simply says "patient prefers Wegovy" will not satisfy the step-therapy requirement. The note must explain why phentermine is contraindicated for this patient (for example, citing a diagnosis of tachyarrhythmia, hyperthyroidism, concurrent MAOI use, or a documented prior adverse reaction) and should include the relevant ICD-10 code. Once that language is in the chart, your appeal can reference it directly.

My BMI is 28 and I have sleep apnea — does Anthem cover GLP-1 medications for me?

Yes, Anthem's policy covers patients with a BMI of 27 or higher if they have at least one recognized comorbidity, and Obstructive sleep apnea is explicitly listed as a qualifying condition. A BMI of 28 with a documented sleep apnea diagnosis satisfies the BMI/comorbidity gate. The key is that both the BMI measurement and the sleep apnea diagnosis must appear in your medical record and be included in the prior authorization submission. If the authorization was submitted without the comorbidity diagnosis code, that is a correctable error — not a legitimate medical denial.

What if my Anthem plan excludes weight-loss drugs entirely under an N-130 denial?

A plan-exclusion denial is harder to overturn than a medical necessity denial, but it is not automatically final. First, review your Summary Plan Description carefully — if the exclusion language does not specifically name GLP-1 medications or "weight-loss drugs," argue that the denial misapplies the exclusion. Second, if you have Type 2 Diabetes, Wegovy and Ozempic (semaglutide) have FDA indications for cardiovascular risk reduction in addition to weight management; reframing the request as cardiovascular pharmacotherapy rather than a weight-loss drug may change which benefit tier applies. Third, if this is an employer-sponsored plan, raise the issue with your HR or benefits department — employers can waive plan limitations and some have done so in response to member advocacy.

How long do I have to file an appeal with Anthem after a denial?

You have 180 days from the date on the denial notice to file your first internal appeal with Anthem. This is a relatively generous window compared to some insurers, but it is a hard deadline — missing it typically eliminates your right to internal review and significantly limits your external review options. File as soon as your documentation is complete, not at the last minute, because Anthem's response clock (30 days for pre-service appeals) doesn't start until they receive your submission.

Can I request an expedited appeal if I need the medication urgently?

An expedited (urgent) appeal is available when the standard timeline could seriously jeopardize your health. For a GLP-1 medication, this is most likely to apply if you have a cardiovascular condition or uncontrolled Type 2 Diabetes for which the medication is considered medically necessary to prevent near-term harm. Under 29 CFR 2560.503-1, Anthem must respond to an expedited pre-service appeal within 72 hours. Ask your physician to include a written statement of clinical urgency with your appeal submission, explaining specifically why a delay poses a health risk.

Get a physician-ready appeal letter in 30 minutes

Writing an appeal letter that correctly quotes Anthem's Clinical UM Guideline, cites the right clinical guidelines, and maps every criterion to a specific chart note takes time — and getting any part of it wrong weakens your case. PriorAuthAppeal offers a service ($59, with a money-back guarantee if your physician declines to sign) that generates a physician-ready appeal letter tailored to Anthem's specific policy criteria, pre-populated with the correct guideline citations and denial-code language. That said, everything you need to write a strong appeal yourself is in this guide. The Anthem Clinical UM Guideline: Anti-Obesity Agents is publicly available at anthem.com/provider in the Clinical UM Guidelines section — download it, read the exact criteria, and make sure your letter addresses each one by name. Whether you write it yourself or use a service, a specific, well-documented appeal grounded in Anthem's own policy language is your strongest possible next step.